Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1227.4 41.7 (3.52%) Market Cap: 719.18 Bil Enterprise Value: 719.74 Bil PE Ratio: 21.89 PB Ratio: 2.33 GF Score: 92/100

Q3 2020 Aurobindo Pharma Ltd Earnings Call Transcript

Feb 07, 2020 / 03:00AM GMT
Release Date Price: ₹546.55 (+7.06%)
Operator

Ladies and gentlemen, good day, and welcome to the Q3 FY '20 earnings conference call of Aurobindo Pharma Limited. (Operator Instructions) Please note that this conference is being recorded.

I would now like to hand the conference over to Mr. Krishna Kiran, Investor Relations. Thank you, and over to you, sir.

Krishna Kiran
Aurobindo Pharma Limited - IR Officer

Thank you, Janice. Good morning, and a warm welcome to our third quarter FY '20 earnings call. I am Krishna Kiran from the Aurobindo Pharma Investor Relations. We hope you have received the Q3 financials and the press release that we have sent out yesterday. These are also available on our website.

With me, we have our senior management team represented by Mr. P.V. Ram Prasad Reddy, Executive Chairman, Aurobindo Pharma USA; Mr. N. Govindarajan, Managing Director; Mr. Sanjeev Dani, COO, Head Formulation; Mr. Santhanam Subramanian, CFO; and Mr. Swami Iyer, CFO, Aurobindo Pharma USA.

We will begin the call with summary highlights from the management, followed by an interactive Q

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot